Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Fluid Biomed

Request full access

Developing an innovative brain stent to heal aneurysms

Calgary, CanadaFounded 2012Health Tech & Medtech

About Fluid Biomed

Fluid Biomed is at the forefront of medical innovation, developing a groundbreaking solution for the treatment of brain aneurysms. The company has designed the world's first hybrid polymer-metal flow-diverting stent, a revolutionary medical device aimed at curing this potentially deadly condition. This innovative stent is uniquely constructed using a combination of dissolving polymer and metal, providing a scaffold that promotes better healing and improved visualization of blood vessels. The device is engineered to be highly flexible, allowing for easy navigation through the delicate blood vessels of the brain using standard techniques familiar to physicians. The stent's design is particularly noteworthy for its ability to gradually integrate into the blood vessel wall after curing the aneurysm, leaving minimal long-term impact. This feature, coupled with the polymer's invisibility to x-rays and its eventual dissolution, significantly reduces interference with follow-up CT and MRI scans. As a result, patients are spared from undergoing invasive angiogram tests and do not require lifelong blood thinners. Fluid Biomed's stent works by slowing down blood flow inside the weakened area of the blood vessel, allowing the aneurysm to thrombose over time. This process effectively protects patients from the risk of rupture and stroke while maintaining normal blood flow to other areas of the brain. Laboratory data suggests that the unique construction of this hybrid polymer-metal stent provides excellent flow-diversion properties, matching or exceeding the performance of existing metal flow-diverters in the market. The company's commitment to patient safety, treatment efficacy, and physician ease-of-use is evident in their approach to product development. With a team comprising academic specialists and practicing neurosurgeons, Fluid Biomed is well-positioned to optimize their medical device for real-world application, potentially revolutionizing the treatment of brain aneurysms and significantly improving patient outcomes.

Source: Dealroom company data

At a glance

Status
Operational
Employees
36
Open positions
None listed
Dealroom signal
77.4/100
Industry
Health
Sub-industry
Medical Devices
Sector
Neurology, Metal Stent Technology, Spinout, Sustainable Development Goals, Polymers, Start Alberta, DT and LS, science-based
Technology
Deep Tech
Business model
Manufacturing
Client focus
B2B

Funding history

7 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Dec 2024 $27M $108M IAG Capital Partners · ShangBay Capital · METIS innovative · LifeArc Ventures ↗
SEED✓Equity / VC Aug 2021 $4.7M $19M Amino Capital · Wharton Alumni Angels of Silicon Valley · Threshold Impact · ShangBay Capital ↗
Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

Fluid Biomed website traffic

Latest recorded traffic for Fluid Biomed is 1.9K monthly website visits, up 251.9% over the last three months. Fluid Biomed's team declined 2.7% over the past year.

Latest monthly visits1.9K 3-month web change+251.9% 1-year team growth-2.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Fluid Biomed in the Calgary ecosystem

Live from Dealroom

The Fluid Biomed office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

17 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed9 investors entered at this stage

  • Thin Air Labs
  • ShangBay Capital
  • METIS innovative
  • Amino Capital
  • Wharton Alumni Angels of Silicon Valley
  • Threshold Impact
  • UCeed Investment Funds
  • Bluesky Equities
  • Alabaster

Series A3 investors entered at this stage

  • Amplitude Ventures
  • IAG Capital Partners
  • LifeArc Ventures

Other known investors5 additional known investors

  • University of Calgary
  • Accelerate Fund
  • Creative Destruction Lab
  • Innovate Calgary
  • UCeed - University of Calgary
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇨🇦 Canada89.7%
🇺🇸 United States6.9%
🇬🇧 United Kingdom3.5%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Fluid Biomed on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Fluid Biomed’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.